Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Withdrawn) A pharmaceutical composition compromising a virally-safe plasma-derived Factor VIII obtained by filtering through a nanometric filter having a pore

size of 13 nm to 25 nm, wherein the filtrate comprises the virally-safe plasma derived Factor VIII solution having a von Willebrand Factor (vWF) content of 15 % or less of decamers and higher multimers.

2. (Withdrawn) The pharmaceutical composition claim 1, wherein the titre reduction factor of a virus having a size of 24 to 30 nm is 4 log or more, 6 log as compared with the solution before filtration.

3. (Withdrawn) The pharmaceutical composition of claim 1, which is in the form of an injectable solution.

4. (Withdrawn) A method for testing the viral safety of a plasma-derived Factor VIII composition obtained by nanometric filtering, comprising the step of

determining the residual content of high multimerisation vWF.

5. (Withdrawn) The method of claim 4, wherein a determination of the residual content of less than 15 % vWF decamers and higher multimers after nanometric filtration indicates that said composition is virally safe.

6. (Withdrawn) The method as of claim 5, wherein a determination of the residual content characterized in that the detection of less than 15 % vWF decamers and highermultimers is correlated with a reduction factor of virus titre of at least 4 log.

7. (Currently Amended) A method for preparing a virally safe Factor VIII solution, the method comprising:

filtering a solution comprising Factor VIII through nanometric filters having a pore size of 13 nm to 25 nm; ~~and~~ assaying the filtrate to determine the residual content of high multimerization von Willebrand Factor (vWF) ~~vWF~~; and correlating the residual content of high multimerization vWF with viral safety.

8. (Previously Presented) The method of claim 7, wherein the step of assaying the filtrate includes verifying that the content of vWF decamers and higher multimers is 15 % or less.

9. (Currently Amended) The method of claim 7, wherein a vWF decamer and higher multimer content of 15 % or less indicates that the titre reduction factor of a virus having a ~~size~~ diameter of 24 nm to 30 nm is 4 log or more, to about 6 log as compared with the solution before filtration.

10. (Canceled)

11. (Withdrawn) A pharmaceutical composition comprising virally-safe plasma-derived Factor VIII having a von Willebrand Factor (vWF) contents of about 15% of less or less decamers and higher multimers.

12. (Withdrawn) The pharmaceutical composition of claim 11 for use in treating diseases related to blood coagulation.

13. (Withdrawn) The pharmaceutical composition of claim 12 for use in treating haemophilia.

14. (Withdrawn) The pharmaceutical composition of claim 1, wherein the titre reduction factor of a virus having a size of 24 nm to 30 nm is 5 log as compared with the solution before filtration.

15. (Withdrawn) The pharmaceutical composition of claim 1, wherein the titre reduction factor of a virus having a size of 24 nm to 30 nm is 6 log as compared with the solution before filtration.

16. (Currently Amended) The method of claim 7, wherein a vWF decamer and higher multimer content of 15 % or less indicates that the titre reduction factor of a virus having a size of 24 nm to 30 nm is 5 log ~~ore~~ or more, to about 6 log as compared with the solution before filtration.

17. (Currently Amended) The method of claim 7, wherein a vWF decamer and higher multimer content of 15 % or less indicates that the titre reduction factor of a virus having a size of 24 nm to 30 nm is ~~6 log ore more, to~~ about 6 log as compared with the solution before filtration.

18. (Withdrawn) A pharmaceutical composition comprising a virally-safe plasma-derived Factor VIII having a von Willebrand Factor content of 15% or less of decamers and higher mutimers.